drugset / Trial / NCT06847464

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

NCT06847464

Phase 1 Completed 48 enrolled Enanta Pharmaceuticals, Inc
Non-randomizedSequentialOpen-labelBasic science

Summary

The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.

Timeline

Start
2025-01-27
Primary completion
2025-05-24
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EDP-323 Unknown
Background Carbamazepine Small molecule
Background Fluconazole Small molecule
Background Itraconazole Small molecule
Background Quinidine Small molecule